$康乃德生物(CNTB)$ Connect Biopharma (CNTB) is terminating its in-license agreement for CBP-174, an antiallergic, with Pfizer (PFE), effective May, to optimize resources and extend its cash runway

Connect Biopharma（CNTB）将终止与辉瑞（PFE）签订的抗过敏药 CBP-174 的许可协议，该协议将于5月生效，以优化资源并延长其现金流道

The company said Tuesday is also postponing all pre-clinical and discovery programs.

该公司周二表示，还将推迟所有临床前和发现项目